HA
BNR

HHLR Advisors’s Burning Rock Biotech BNR Stock Holding History

HHLR Advisors’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,000
Closed -$10M – 98
2020
Q3 		$10M Hold
40,000
– – 0.08% 63
2020
Q2 		$10.8M Buy
+40,000
New +$11M 0.1% 54

Other funds holding BNR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

HHLR Advisors's BNR Position: Q4 2020 in Review

HHLR Advisors sold out of Burning Rock Biotech (BNR) in Q4 2020, closing a stake of 40,000 shares — an estimated $10M sold.

HHLR Advisors first reported a position in BNR in Q2 2020 and held it in 2 quarters. The position peaked at $10.8M in Q2 2020. 58 funds tracked by Wall St. Rank hold BNR as of Q4 2020.

  • HHLR Advisors reported no remaining Burning Rock Biotech position as of Q4 2020 after selling out during the quarter.
  • HHLR Advisors sold 40,000 Burning Rock Biotech shares in Q4 2020, an estimated $10M.
  • HHLR Advisors first reported a position in Burning Rock Biotech in Q2 2020 and held it in 2 quarters.
  • HHLR Advisors's Burning Rock Biotech position peaked at $10.8M in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2020.

Based on HHLR Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.